SOUTH SAN FRANCISCO, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 9:00 a.m. PST. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
A live webcast of the presentation will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio’s programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434 and ATA 842. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
Source:Atara Biotherapeutics, Inc.